Effect of Influenza Vaccination on Rate of Influenza Virus Infection in Chinese Military Personnel, 2015–2016: A Cluster Randomized Trial
Author:
Li Yapin1, Yu Jianxing2, Li Qingfeng1, Yu Dan2, Song Wenjing1, Liu Qi3ORCID, Gao Dongqi1, Chen Qiulan2, Zhang Haiyang1, Huo Liqun2, Wang Jian1, Wang Jiayi3, Yang Huisuo1, Zeng Gang2
Affiliation:
1. Central Theater Command Center for Disease Control and Prevention, No. 66 Heishitou Road, Beijing 100042, China 2. Sinovac Biotech Ltd., No. 39, Shangdi West Road, Beijing 100085, China 3. Sinovac Life Sciences Ltd., Beijing 102601, China
Abstract
Influenza is a major cause of morbidity and mortality. The protective effect of a trivalent influenza vaccine (TIV) is undetermined in military personnel. We conducted an open-label, cluster randomized trial on active-duty servicemen of Beijing, Tianjin, and Shijiazhuang, who were randomly assigned to receive either a single dose of TIV or no treatment, according to cluster randomized sampling. The subjects were then followed for a maximum of six months to assess the incidence of laboratory-confirmed influenza. A total of 5445 subjects in 114 clusters received one dose of TIV before the 2015/2016 influenza season. Laboratory-confirmed influenza was identified in 18 in the vaccine group compared with 87 in the control group (6031 subjects in 114 clusters), resulting in a vaccine effectiveness (VE) of 76.4% (95%CI: 60.7 to 85.8) against laboratory-confirmed influenza. Influenza-like illness was diagnosed in 132 in the vaccine group compared with 420 in the control group, resulting in a VE of 64.1% (95%CI: 56.2 to 70.6). The estimated VE against influenza B viruses was 80.5% (95%CI: 65.6 to 88.9) and 8.6% (95%CI: −241 to 75.5) against influenza A viruses. In conclusion, the trivalent influenza vaccine is moderately effective, highly immunogenic, and generally safe to use in healthy male military servicemen.
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference39 articles.
1. Estimates of global seasonal influenza-associated respiratory mortality: A modelling study;Iuliano;Lancet,2018 2. World Health Organization (2022). Vaccines against influenza: WHO position paper—May 2022. Wkly. Epidemiol. Rec., 97, 185–208. 3. Influenza-associated excess respiratory mortality in China, 2010–15: A population-based study;Li;Lancet Public Health,2019 4. Vaccines for preventing influenza in healthy children;Jefferson;Cochrane Database Syst. Rev.,2018 5. Demicheli, V., Jefferson, T., Di Pietrantonj, C., Ferroni, E., Thorning, S., Thomas, R.E., and Rivetti, A. (2018). Vaccines for preventing influenza in the elderly. Cochrane Database Syst. Rev.
|
|